Literature DB >> 25196769

Proliferative vitreoretinopathy.

Carl Claes1, Anna Paula Lafetá.   

Abstract

Proliferative vitreoretinopathy is a sophisticated disease that complicates vitreoretinal pathologies like retinal detachments. Since its first description in the 1960s, we have learned a lot about this pathological entity; however, despite a large number of promising laboratory and clinical pharmacological research projects, we are still unable to stop proliferation and are certainly not able to prevent this terrible complication. As a result, vitreoretinal surgeons still have to fight membrane formation in complicated and long vitreoretinal procedures. Fortunately, a revolution has taken place in equipment for these procedures. This chapter will examine the pathophysiology, classification, and pharmacotherapy, and describe the strategy and rationale of how to deal with this recurrent condition and to limit and contain its sequelae.
© 2014 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2014        PMID: 25196769     DOI: 10.1159/000360466

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  8 in total

1.  Comparative transcriptomic analysis reveals adriamycin-induced apoptosis via p53 signaling pathway in retinal pigment epithelial cells.

Authors:  Yu-Chen Lin; Ze-Ren Shen; Xiao-Hui Song; Xin Liu; Ke Yao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Dec.       Impact factor: 3.066

2.  Combined pars plana vitrectomy-scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy.

Authors:  Frank H P Lai; Ernie C F Lo; Vesta C K Chan; Mårten Brelen; Wai Ling Lo; Alvin L Young
Journal:  Int Ophthalmol       Date:  2015-08-11       Impact factor: 2.031

3.  Magnetic nanoparticles: a strategy to target the choroidal layer in the posterior segment of the eye.

Authors:  Martina Giannaccini; Lucia Pedicini; Guglielma De Matienzo; Federica Chiellini; Luciana Dente; Vittoria Raffa
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

4.  Gremlin mediates the TGF-β-induced induction of profibrogenic genes in human retinal pigment epithelial cells.

Authors:  Dong Qin; Xuemin Jin; Yanrong Jiang
Journal:  Exp Ther Med       Date:  2020-01-21       Impact factor: 2.447

5.  Doxycycline Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy in Mice.

Authors:  Shun-Hua Chen; Yu-Jheng Lin; Li-Chiu Wang; Hsien-Yang Tsai; Chang-Hao Yang; Yu-Ti Teng; Sheng-Min Hsu
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

6.  Exosomal miR-4488 and miR-1273g-5p inhibit the epithelial-mesenchymal transition of transforming growth factor β2-mediated retinal pigment epithelial cells by targeting ATP-binding cassette A4.

Authors:  Hongtao Dong; Menghua Wang; Qiuming Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Intravitreal methotrexate infusion for proliferative vitreoretinopathy.

Authors:  Ama Sadaka; Robert A Sisk; James M Osher; Okan Toygar; Melinda K Duncan; Christopher D Riemann
Journal:  Clin Ophthalmol       Date:  2016-09-19

Review 8.  Gene-Based Therapeutics for Acquired Retinal Disease: Opportunities and Progress.

Authors:  Tien-En Tan; Beau James Fenner; Veluchamy Amutha Barathi; Sai Bo Bo Tun; Yeo Sia Wey; Andrew Shih Hsiang Tsai; Xinyi Su; Shu Yen Lee; Chui Ming Gemmy Cheung; Tien Yin Wong; Jodhbir Singh Mehta; Kelvin Yi Chong Teo
Journal:  Front Genet       Date:  2021-12-07       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.